263 related articles for article (PubMed ID: 12874760)
1. Down-regulation of drs mRNA in human prostate carcinomas.
Kim CJ; Shimakage M; Kushima R; Mukaisho K; Shinka T; Okada Y; Inoue H
Hum Pathol; 2003 Jul; 34(7):654-7. PubMed ID: 12874760
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of drs mRNA in human colon adenocarcinomas.
Shimakage M; Kawahara K; Kikkawa N; Sasagawa T; Yutsudo M; Inoue H
Int J Cancer; 2000 Jul; 87(1):5-11. PubMed ID: 10861446
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
5. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
6. Expression of drs mRNA in human lung adenocarcinomas.
Shimakage M; Takami K; Kodama K; Mano M; Yutsudo M; Inoue H
Hum Pathol; 2002 Jun; 33(6):615-9. PubMed ID: 12152160
[TBL] [Abstract][Full Text] [Related]
7. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.
Chakrabarti R; Robles LD; Gibson J; Muroski M
Cancer Genet Cytogenet; 2002 Dec; 139(2):115-25. PubMed ID: 12550771
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
[TBL] [Abstract][Full Text] [Related]
9. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.
Chi SG; deVere White RW; Muenzer JT; Gumerlock PH
Clin Cancer Res; 1997 Oct; 3(10):1889-97. PubMed ID: 9815578
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of drs mRNA in colorectal neoplasms.
Mukaisho K; Suo M; Shimakage M; Kushima R; Inoue H; Hattori T
Jpn J Cancer Res; 2002 Aug; 93(8):888-93. PubMed ID: 12716466
[TBL] [Abstract][Full Text] [Related]
12. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
13. Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium.
Woessner RD; Wright PS; Loudy DE; Wallace CD; Montgomery LR; Nestok BR
Exp Mol Pathol; 1998; 65(1):37-52. PubMed ID: 9613925
[TBL] [Abstract][Full Text] [Related]
14. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
Bethel CR; Faith D; Li X; Guan B; Hicks JL; Lan F; Jenkins RB; Bieberich CJ; De Marzo AM
Cancer Res; 2006 Nov; 66(22):10683-90. PubMed ID: 17108105
[TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
16. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells.
Grzmil M; Thelen P; Hemmerlein B; Schweyer S; Voigt S; Mury D; Burfeind P
Am J Pathol; 2003 Aug; 163(2):543-52. PubMed ID: 12875974
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.
Zhou T; Xu C; He M; Sun Y
Prostate Cancer Prostatic Dis; 2008; 11(2):143-7. PubMed ID: 17637760
[TBL] [Abstract][Full Text] [Related]
19. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
